Progress of Study on Cytokines in Myeloproliferative Neoplasms.
10.7534/j.issn.1009-2137.2015.03.053
- Author:
Cong-Cong SUN
1
;
Ying LI
2
Author Information
1. Department of Hematology, Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong Province, China.
2. Department of Hematology, Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong Province, China. E-mail: liyjn@126.com.
- Publication Type:Journal Article
- MeSH:
Bone Marrow Neoplasms;
Cytokines;
Humans;
Myeloproliferative Disorders;
Prognosis
- From:
Journal of Experimental Hematology
2015;23(3):878-882
- CountryChina
- Language:Chinese
-
Abstract:
The clonal blood disorder, such as polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms(MPN) and are specified by increased production of terminally differentiated myeloid cells. Abnormal expression and activities of a number of proinflammatory cytokines are associated with MPN, in which immune dysregulation is pronounced as evidenced by the dysregulation of several immune and inflammation genes. It is becoming increasingly clear that the dysregulation of cytokine levels contributes to the pathophysiology of MPN and they are prognostic indicators. In this review, the role of cytokines in the pathogenesis of MPN, the clinical relevance of cytokines with MPN, current therapies and the combination with the new treatments targeting cytokines are summarized.
